logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Bisphosphonate class drugs

    FiltersReset Filters
    9 results

    • alendronate

      (ALENDRONATE SODIUM)
      Hangzhou Minsheng Binjiang Pharmaceutical Co., Ltd.
      Usage: Alendronate sodium tablets are indicated for treating and preventing osteoporosis in postmenopausal women, increasing bone mass in men with osteoporosis, treating glucocorticoid-induced osteoporosis, and treating Paget’s disease of bone. Use should be periodically re-evaluated, particularly for low-risk fracture patients after 3 to 5 years.

    • alendronate sodium

      (Alendronate Sodium)
      Hikma Pharmaceuticals USA Inc.
      Usage: Alendronate sodium is indicated for treating osteoporosis in postmenopausal women and increasing bone mass in men with osteoporosis. It helps increase bone mass and reduce fracture incidence, particularly in the hip and spine. Re-evaluations for continued therapy are recommended every few years.

    • fosamax

      (alendronate sodium)
      Organon LLC
      Usage: FOSAMAX is indicated for treating and preventing osteoporosis in postmenopausal women, increasing bone mass in men with osteoporosis, treating glucocorticoid-induced osteoporosis, and managing Paget's disease of bone. It enhances bone mass and reduces fracture incidence across these conditions. Regular reassessment for continued therapy is recommended.

    • fosamax plus d

      (ALENDRONATE SODIUM and CHOLECALCIFEROL)
      Organon LLC
      Usage: FOSAMAX PLUS D is indicated for treating osteoporosis in postmenopausal women and increasing bone mass in men with osteoporosis. It enhances bone mass and lowers the risk of fractures, but is not for treating vitamin D deficiency. Optimal duration and need for continued therapy must be periodically reassessed.

    • ibandronate sodium

      (Ibandronate sodium)
      Dr. Reddy's Laboratories Limited
      Usage: Ibandronate sodium tablets are indicated for the treatment and prevention of osteoporosis in postmenopausal women. They increase bone mineral density and reduce vertebral fractures. Continued therapy needs periodic evaluation, especially after 3 to 5 years for low-risk patients.

    • ibandronate sodium

      (Ibandronate Sodium)
      AuroMedics Pharma LLC
      Usage: Ibandronate sodium injection is indicated for the treatment of osteoporosis in postmenopausal women, increasing bone mineral density and reducing vertebral fracture incidence. Safety and effectiveness are based on one-year clinical data, with the optimal treatment duration yet to be determined. Regular reevaluation is essential.

    • ibandronate sodium

      (IBANDRONATE SODIUM)
      Apotex Corp
      Usage: Ibandronate sodium tablets are indicated for the treatment and prevention of postmenopausal osteoporosis, increasing bone mineral density and reducing vertebral fractures. Optimal duration of use is not established; reevaluation of therapy need is recommended after 3-5 years, especially for low-risk fracture patients.

    • ibandronate sodium

      (IBANDRONATE SODIUM)
      Macleods Pharmaceuticals Limited
      Usage: Ibandronate sodium tablets are indicated for treating and preventing postmenopausal osteoporosis, increasing bone mineral density and reducing vertebral fracture incidence. Ongoing therapy should be periodically re-evaluated, especially in patients at low fracture risk, who may consider discontinuation after 3 to 5 years of use.

    • ibandronate sodium

      (ibandronate sodium)
      Apotex Corp.
      Usage: Ibandronate sodium injection is indicated for treating osteoporosis in postmenopausal women, enhancing bone mineral density and decreasing vertebral fracture incidence. Its safety and effectiveness are primarily based on one-year clinical data, with ongoing assessment of therapy necessity recommended for patients.